Objective. To establish evidence-based and experts' opinion filtered statements on the optimal treatment choice between cycling (switch) and changing mode of action strategies (swap) in RA patients failing TNF inhibitors (TNFis).
Introduction
Biologic DMARDs (bDMARDs) have dramatically improved the management of RA patients failing conventional therapies. Several bDMARDs have been approved both as first and as second line therapies, with a general and actual trend by rheumatologists of commencing TNF inhibitors (TNFis) as primary choice, due to the more robust data on their long-term efficacy and safety compared with other more recently introduced bDMARDs with different mode of action (MoA). However, almost 30% of patients do not respond (or respond suboptimally) to TNFi, failing to maintain an initially good response over time or experiencing adverse events (AEs) leading to treatment discontinuation [1] . Existing recommendations (Table 1 ), in line with published scientific data integrated with experts' opinions, offer evidence-based flow-charts in cases of failure of one or more TNFis in RA patients [25] . All these sets of recommendations agree in suggesting a different MoA bDMARD when two or more TNFis have failed, recognizing that efficacy might decline when cycling to a third or fourth TNFi. On the contrary, in the case of failure of the first TNFi, no strong evidence seems to support one strategy over another, so that the therapeutic choice is left to the experience of the treating physician, who should take into consideration also patient and disease characteristics. In this setting, switching to a second anti-TNF agent (cycling strategy) or adopting an alternative class of targeted agents with a different MoA (swapping strategy) might both be considered as alternative available strategies, but the optimal treatment approach has yet to be defined. In the 2013 and 2016 set of European recommendations from the EULAR, the corresponding topic similarly states that 'if a bDMARD or tsDMARD [targeted synthetic DMARD] has failed, treatment with another bDMARD or a tsDMARD should be considered; if one TNF inhibitor therapy has failed, patients may receive another TNF inhibitor or an agent with another mode of action' [3, 5] . Once again, no standardized approach was defined, still suggesting that TNFi cycling might offer further gain in clinical control when a first TNFi failed to obtain the target. Anyway, from available scientific evidence, some considerations about this topic should be derived for the decision making process: as demonstrated in real life settings, clinical response tends to decline with the increasing number of previous TNFis adopted and, in addition, the reason for discontinuation of the first TNFi seems to affect the response to the second one [6] . Moving from this background and dealing with this relevant definitive gap in the existing treatment recommendations, we retrieved available literature evidence on the clinical performance (efficacy and safety) of cycling vs swapping strategies in RA patients failing TNFi therapy, in order to eventually derive more definitive conclusions.
Methods
The literature review was conducted through PubMed and EMBASE databases to identify all English-language articles fitting the pre-specified topic of cycling (Intervention, I) vs swapping strategies (Comparison, C) with respect to efficacy and safety (Outcomes, O) in adult RA patients (Population, P) failing a TNF inhibitor (as first or subsequent line of treatment), regardless of the underlying reason (inefficacy, primary or secondary, or AEs). The literature review was extended from the 2013 update of the EULAR RA recommendations (8 April 2013) up to 15 January 2016, using appropriate key words and Medical Subjects Headings for disease (RA) and bDMARD names (infliximab/IFX, etanercept/ETA, adalimumab/ADA, golimumab/GOL, certolizumab pegol/CZP, abatacept/ABA, rituximab/RTX, tocilizumab/TCZ). The research was performed either by crossing each single TNFi with every non-TNF bDMARD or by considering all TNFi agents as a class vs non-anti-TNFs single agents. The EMBASE search was carried on through population, intervention, comparison and outcome and also advanced strategies. Additionally, the bibliography of relevant articles was hand-searched for identification of other potentially suitable studies. The research was designed and performed by one author (M.T.). All available scientific evidence (Table 2) coming from meta-analyses, randomized controlled trials (RCTs), national registries of biologics and national healthcare databases has been considered for data extraction, whenever considering clinical efficacy endpoints as primary outcomes; safety issues were evaluated as secondary outcomes. Narrative reviews, editorials, scientific conference abstracts and case reports have been excluded from this work. The hierarchy of study types was indicated by levels of evidence as suggested by the Oxford Centre for Evidence-based Medicine (http://www.cebm.net/oxford-centre-evidencebased-medicine-levels-evidence-march-2009/). Preliminary statements based on available results have been presented in line with their level of evidence, discussed, eventually reformulated and voted through a Delphi method during a national consensus of a panel of Italian rheumatologists. In this article, all the steps dealing with the swap vs switch strategy will be presented. We followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines for preparing the article (http://www.prisma-statement.org/).
Results

General results
Globally, 12 out of 365 full-text articles dealing with cycling vs swapping strategies in adult RA patients failing at least one TNFi were selected for final evaluation [718] . Three studies had been conducted in Japanese populations: one of them, from the REAL Registry, considered only safety issues between tocilizumab (TCZ) and TNFi in patients failing previous unspecified bDMARDs (in 71 and 11% of patients, respectively, in the two groups) [11, 13, 15] . This study was subsequently deleted from the final analysis for incomplete and unavailable relevant informative data [11] . One report from Navarro-Coy was a studyprotocol with no available results at the date this article was submitted [14] . Supplementary Fig. S1 shows the corresponding article flow-chart.
Background data pro-cycling
Several uncontrolled studies suggested benefit in switching between TNFis [6, 1926, 28] . The rationale for switching between different TNFis was strengthened by a large, randomized, industry-led efficacy study comparing golimumab (GOL) with placebo (GO-AFTER trial) [29] . This phase III study involved 461 patients, who had previously received and either failed or were intolerant to one or more TNFis, that were randomized to placebo or subcutaneous GOL 50 or 100 mg every 4 weeks. Globally, primary and secondary endpoints were more frequently achieved in patients in the active arm (CZP), with ACR20 response rate at week 12 being 51.1% compared with 25.9% for placebo (P < 0.001) and ACR50 and ACR70 response rates 26.6 and 12.9% for the CZP group compared with 9.9 and 2.8% for placebo, respectively (P < 0.001 for each comparison). CZP efficacy was consistent across the subgroups, even when stratified by previous TNFi use, concomitant use of MTX and disease duration. Specifically, ACR20 response rates were numerically higher in patients without previous TNFi use than in those with previous TNFi use, although the treatment interactions were not significant. Similar proportions of CZP patients previously receiving one or two TNFis achieved ACR20 response rates at week 12 (46.7 vs 48.2%, respectively), regardless of whether they received ADA (45.0%), ETA (52.4%) or IFX (46.4%). In addition to these data, more recently (out of the time frame of our systematic search) the first head-to-head trial in TNFiexperienced RA patients has been published, showing a good efficacy of cycling to a second TNFi even after primary insufficient response to the first one. The EXXELERATE study is the first prospective, single blind (double blinded to week 12 and investigator blinded thereafter) trial assessing in RA patients on MTX background firstly the efficacy of CZP compared with ADA with a primary superiority end point at 12 weeks and 2 years, secondly the comparative efficacy of cycling (from CZP to ADA and viceversa) in primary non-responders at week 12 without a wash-out period [31] . The results in the predefined analyses showed no superiority of CZP at the short-term and long-term endpoints, along with a comparable safety profile over 2 years. Importantly, in this study, among patients with a primary inadequate response to the first TNFi, a similar proportion of subjects responded after cycling to a second TNFi: 58% of patients switching to CZP and 62% of patients switching to ADA became responders 12 weeks later, thus providing additional clinical evidence of the efficacy and safety of an immediate switch to a second TNFi in a primary TNFi inadequate responder population. Such uncontrolled and controlled data from real life and clinical trials settings confirm that cycling strategy is a suitable approach in patients failing one or more TNFis, with a general trend of better clinical gain in first-switcher patients rather than in subjects not responding to two or more TNFis. ; P = 0.004) in favour of swapping strategy. With several limits in mind (lack of blinding of participants, some bDMARDs such as GOL not allowed, unpowered for individual drug differences, bDMARD monotherapy in at least 40% of cases), these results seem to support the choice of a non-TNF biologic agent after a first TNFi failure.
Results pro-swap
In line with the pre-specified limits of the performed systematic review, data supporting a swapping strategy are limited in terms of both quality and quantity ( Table 3 ). The vast majority of data comes from open label retrospective or prospective observational trials. In an Italian retrospective monocentric analysis, among 201 RA non-responder patients to the first TNFi (mainly due to non-toxic causes, but with no specification of primary vs secondary non-response), survival on therapy with a second line bDMARD was significantly higher in the swapping than in the cycling group [16] . After adjustment and matching for propensity score, probability of treatment retention in the swapping group was significantly higher (hazard ratio = 2.258, 95% CI: Considering TCZ, in the multicentre retrospective analysis by Backhaus, TCZ both as mono-or combo-therapy with csDMARDs was significantly better than TNFi as monocombo-therapy in 1603 patients failing a csDMARD or a previous course of TNFi in terms of achievement of DAS28 remission at 12 weeks (pre-specified primary outcome of the study). In the specific subset of previous TNFi failing patients, the pre-defined target of clinical remission was obtained in 41% in TCZ + csDMARDs vs 19% in the second TNFi + csDMARDs (P < 0.001). Globally, TCZ monotherapy was more efficacious than TNFi monotherapy in patients failing a previous csDMARD or a first TNFi, considered as a global population (DAS28 remission 37.2% vs 30.2%, respectively, P < 0.001). Similar results in favour of TCZ vs another TNFi (cycling strategy) were obtained with other outcomes not including acute phase reactants, such as mean Clinical Disease Activity Index (CDAI) difference from baseline to 3 months, and with patient-reported outcomes, such as Visual Analogue Scale for Patient's Global Assessment (VAS-PGA), VAS-pain and morning stiffness, thus avoiding eventual over-results due to TCZ effects on serum inflammatory biomarkers. As a limit of this study, the authors stated that long-term results are obviously required to confirm such short-term data, which represent the cut-off time point to assess primary response to bDMARDs in accordance with EULAR guidelines [3] . Anyway, in accordance with this, it seems that in the short term TCZ might offer higher clinical efficacy compared with TNFi after previous TNFi failure, with no current information about the maintenance of the benefits over time.
Additional data regarding RTX and ABA in TNFi failure patients come from two retrospective reports from the CORRONA registry by Harrold et al.: in the stratifiedmatched population (failures of at least one TNFi), ABA offered no advantage (mean CDAI modification, ACR20/ 50/70 responses, HAQ improvement) over a further TNFi both at 6 and 12 months of follow-up, while RTX users had significantly higher probability of achieving low disease activity, ACR20 response and HAQ improvement [8, 18] .
Overall, available data seem to confirm that changing mode of action might be a better option, especially in seropositive patients failing a first TNFi due to inefficacy (results in favour of RTX vs another TNFi) or in patients requiring bDMARD monotherapy (results in favour of TCZ monotherapy vs another TNFi monotherapy).
Results pro-similar performance cycling vs swapping
In the absence, within the pre-specified time frame of the review, of direct head-to-head trials comparing bDMARDs with different MoA in TNFi failure patients, indirect metaanalysis has emerged as an accepted and valid methodology for comparing drugs with each other using a common comparator (placebo or a synthetic DMARD). The best quality data indirectly comparing switching vs swapping strategies in TNFi failures come from a network meta-analysis (Tables 3 and 4) , which pooled results from four randomized placebo-controlled trials involving quite homogeneous target populations: the GO-AFTER trial, the RADIATE trial, the REFLEX trial and the ATTAIN trial [17] . All these studies, even if with different proportions, included long-standing RA patients failing one or more TNFis (ADA, IFX, ETA) due to inefficacy or AE, mostly used in combination with csDMARDs. Globally, the proportion of patients who achieved ACR20 was highest for TCZ (62.4%; 95% CI: 49.9, 74.0%), followed by RTX (47.0%; 95% CI: 37.7, 56.6%), ABA (43.7%; 95% CI: 32.9, 55.4%) and GOL (32.1%; 95% CI: 22.3, 44.0%), and lowest for placebo (15.5%; 95% CI: 12.8, 18.5%). Similarly, the ACR50 was higher for TCZ and lower for placebo; RTX had the highest proportion of patients achieving ACR70. According to the clinical evidence to date, these findings suggest that non-TNF biologic agents such as RTX, ABA and TCZ are more effective than TNFi for the treatment of RA patients failing a first TNFi. However, no definite conclusions can be drawn in this setting due to many limitations: short follow-up period, lack of safety analysis along with efficacy data, absence of studies involving cycling to a TNFi different from GOL, lack of sub-analysis stratified by number of previous TNFis. A previous indirect meta-analysis by Schoels involving the same trials underlined the similarity in the ACR50 and 70 response rates for all agents (ABA, GOL, RTX and TCZ), suggesting that all biologic drugs have comparable efficacy in TNFi-failing RA patients, when considering relevant clinical response [41] . In addition, in line with this first report, GOL presented significantly fewer AEs with respect to indirect comparators. Moreover, in sub-analysis stratified by the number of previous TNFi failures, indirect comparison of response rates between GOL and TCZ found very similar rates after one, two or three TNFis, although there was a trend toward significance after three TNFis: the small number of patients in this subgroup represents an important limit of this part of the study. Besides these two meta-analyses, a study by Manders and colleagues [10] published in 2015 tried to compare the effectiveness and cost-effectiveness of three biologic treatments with different MoA in RA patients in which TNFi therapy has failed. In this pragmatic multicentre randomized trial, 139 RA patients failing a first TNFi (due to ineffectiveness or AEs) were allocated to a second TNFi agent (50 patients) or to i.v. ABA or RTX (43 and 46 patients, respectively); TCZ was not yet licensed at the time of the study and thus not analysed. There were no significant differences between the three groups with respect to multiple RA outcomes at 1 year of follow-up (primary outcome: DAS28 and secondary outcomes: HAQ and SF-36); however, the analysis revealed that RTX therapy was significantly more cost-effective than both ABA and TNFi. In other words, all treatment options were similarly clinically effective; however, when costs were factored into the treatment decision, RTX was the best option available for patients whose first TNFi treatment failed. However, generalization of these cost-effective analyses to other countries should be considered carefully, due to possible differences in pharmaco-economic issues. No differences resulted in the performance of a second course of bDMARD in line with cycling (toward ETA) or swapping (to TCZ or ABA) in 89 Japanese RA patients stopping a first TNFi mAb (ADA or IFX) due to inadequate response: similar retention rate and mean CDAI values were observed among patient groups [13] . In another Japanese study, retention rates of a second biologic treatment were compared by the type of first TNFi and second biologic agents: 169 RA patients who failed a first course of TNFi therapy from the Tsurumai Biologics Communication Registry (ADA/IFX, ETA) received a different TNFi or TCZ as a second biologic agent [15] . Adjusting for confounders, drug retention rate of the second biologic agent after switching from IFX/ADA was significantly higher with ETA (90.0%) and TCZ (94.7%) than with ADA/IFX (59.3%); drug retention rate of the second biologic agent after switching from ETA was significantly higher with TCZ (75.9%) than with ADA/IFX (46.3%). In other words, switching from anti-TNF mAb (ADA/IFX) to soluble anti-TNF receptor (ETA) leads to better results than vice versa: as the authors stated, this might be due mainly to the well-known lesser immunogenicity of ETA, thus inducing lower incidence of anti-drug antibodies. Another reason of higher probability of failure after switching from ETA to ADA/IFX rather than vice versa might rely on its additional targeting against lymphotoxin-a (TNF-b), besides TNF-a. Differences in ADAs detection between Japanese and Caucasian patients, possibly related to different MTX dosage adoption and/or different ethnic background, might in part suggest caution when interpreting such results.
Conclusions
No standardized and homogeneous approach has been proposed by existing recommendations for RA patients failing a first TNFi. Several bDMARDs with different MoA are now available for the treatment of this subset of patients, with no proven direct comparison (at the time this systematic review was performed) between alternative options (cycling vs swapping strategies). Moving from this gap in our knowledge, we performed a systematic review trying to update evidence-based information supporting the decision-making process. According to scientific data on this relevant topic published within the pre-defined temporal limits, thus combined and enriched by a national consensus of expert rheumatologists, preliminary statements regarding cycling vs swapping strategies in RA patients failing the first course of TNFis might be formulated as indicated in Table 4 . Thus, up to now, mainly from indirect comparison from RCTs and real life experiences, both strategies might be adopted in cases of first TNFi failure, with some evidence suggesting better performance of swapping over switching.
Reasearch agenda
Since our work was submitted, further evidence had been published on such a relevant topic involving emerging and progressively marketed drugs, such as biosimilars and targeted systemic DMARDs, namely tofacitinib and baricitinib. Specifically, in a systematic review by Singh and coauthors, results have been reported from a network meta-analysis involving 12 trials dealing with subsequent therapies in RA patients failing previous TNFi [42] . Patients were stratified by biologic type (anti-TNF vs non-anti-TNF biologic agents), DMARD background (bDMARD monotherapy vs MTX combo-therapy) and bDMARD dose (standard vs high dose). Considering clinical outcomes, on background MTX and compared with non-TNF agents, TNF biologics were not associated with any statistically significant or clinically meaningful difference in the odds of both clinical remission (OR = 0.75, 95% CI: 0.04, 26.4) and ACR50 response (OR = 0.51, 95% CI: 0.18, 1.54) [42] . Similarly, non-statistically significant differences were seen when comparing tofacitinib to non-TNF (for In case of failure to one or more TNFis (regardless of the reason), switching to another TNFi or swapping to a different MoA agent (+ csDMARDs) could provide similar relevant clinical (ACR50/ACR70) control.
1A 91
Treatment with RTX after TNFi failure might be associated with higher prevalence of infusion reactions respect to i.v. TCZ and ABA.
1A 75
The use of GOL after previous TNFi failure might be associated with less occurrence of AEs with respect to non-anti-TNF bDMARD agents.
1A 86
In seropositive patients (RF and ACPA + ) failing a first TNFi due to inefficacy, swapping to RTX could provide more clinical benefits than switching to a second TNFi. In seropositive patients, failing a first TNFi due to AEs, similar benefits could be obtained with either RTX or a second TNFi.
B 95
Seronegative (RF and ACPA À ) patients failing the first TNFi (regardless of the reason) could gain similar benefits using either a second TNFi or RTX.
B 91
Clinical response at 12 weeks in patients with inadequate response to TNFi has been reported to be higher for TCZ (as mono-or combo-therapy) than TNFis.
B 97
ABA: abatacept; AE: adverse event; bDMARD: biologic DMARD; csDMARD: conventional synthetic DMARD; GOL: golimumab; MoA: mode of action; RTX: rituximab; TNFi: TNF inhibitor; TCZ: tocilizumab.
https://academic.oup.com/rheumatology vii51 Switch or swap strategy in RA patients failing TNFis ACR50 response OR = 0.65, 95% CI: 0.23, 1.86) or TNFi (for ACR50 response OR = 1.26, 95% CI: 0.36, 4.40). No studies examined radiographic progression outcome, so that indirect comparisons on structural endpoints should not be evaluated. Considering safety issues, no significant advantage was reported for one agent over another. Moreover, in a real life setting, Li et al.
[43] demonstrated that only ADA could be as efficacious as non-TNF bDMARD after ETA failure in a large multinational RA population. Nevertheless, TNFis as a class were overall less effective than a second non-TNF-a biologic (EULAR good response rate 56.0 vs 64.4%, P < 0.05 and CDAI score change À6.3 vs À7.3, P = 0.06, respectively). Such a relevant issue could be finally resolved by the future results of the SWITCH trial, whose protocol design has been already published and that includes also global cost-effectiveness evaluation among secondary outcomes [14] .
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